cyrilzakka/clinical-trials huggingface dataset:
Comparison of the Effectiveness of Reformer Pilates and Conventional Physiotherapy in Lumbar Disc Herniation

This study aims to examine the effects of Reformer Pilates on patient-reported outcomes such as pain level, fatigue, sleep quality, anxiety, kinesiophobia, and quality of life in individuals with lumbar disc herniation (LDH) and to compare its effectiveness with conventional physiotherapy protocols.

All participants underwent a rehabilitation program for six weeks. Pre- and post-treatment assessments were conducted, and the results of the groups were compared. The Reformer Pilates group participated in a 12-session Pilates exercise program, performed twice a week for 45-50 minutes per session, while the Conventional Physiotherapy group underwent a 30-session conventional physiotherapy program, performed five days a week for 45-50 minutes per session.

Assessment tools included the McGill-Melzack Pain Questionnaire, Fatigue Severity Scale, Pittsburgh Sleep Quality Index, Beck Anxiety Inventory, Tampa Scale of Kinesiophobia, and SF-36 Quality of Life Scale. Measurements were taken twice: before and after treatment.

In post-treatment group comparisons, a significant difference was found in pain levels in the Reformer Pilates group and fatigue levels in the Conventional Physiotherapy group. Within-group analyses showed significant improvements in pain, fatigue, kinesiophobia, and physical function subdomains in the Reformer Pilates group, while the Conventional Physiotherapy group showed significant improvements in fatigue, anxiety, and kinesiophobia scores.

In conclusion, Reformer Pilates was found to be an effective method for pain management, whereas Conventional Physiotherapy provided more notable benefits for fatigue management. Both methods were effective in managing kinesiophobia and fatigue, highlighting the importance of tailoring treatment plans to meet the individual needs of patients.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 21 and 50 years
* Complaints of low back pain for at least three months
* Diagnosed with lumbar disc herniation
* No spinal surgery in the last six months
* Regular participation in the program
* Ability to communicate
* Exclusion Criteria:
* Presence of systemic diseases affecting pain, such as fibromyalgia
* Presence of neurological or orthopedic disorders
* Receiving physical therapy in the past eight weeks
* Presence of spinal stenosis, spondylolysis, spondylolisthesis, or other lumbar -degenerative diseases
* Pregnancy status
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University

Human Immunodeficiency Virus (HIV) infected patients in the HIV registries of Johns Hopkins University, University of North Carolina and Vanderbilt University will be followed in the routine clinical care to estimate the rates of prespecified clinical events in this population.

All patients identified in the HIV registries will be included without any sampling

Eligibility Criteria:
Inclusion Criteria:

* HIV infection.

Exclusion Criteria:

* None.
Multi-Tiered Systems of Support for Teacher Training in Classroom Management

The goal of this clinical trial is to test the effects of a responsive approach to training teachers to increase their use of evidence-based classroom management practices. The main question to answer is whether teachers increase their use of a target classroom management practice when they receive the intervention. All participants will receive the intervention. The target practice for which they receive intervention will be randomly assigned. Participants will submit videos of an instructional activity in their classroom 1-2 times per week over a period of 12-15 weeks. They will be asked to complete online modules on classroom management practices and to self-monitor their use of one classroom management practice. Participants may also be asked to graph their data, watch videos of themselves teaching, or implement peer coaching with a classmate or other participant. Researchers will compare the change in target classroom management practices between groups to test if the change in the group who targeted the practice is greater than the change in the group who did not target the practice.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled in EDU 502 or PK-12 classroom teacher

Exclusion Criteria:

* Inability to submit video recordings of instruction for data collection and analysis
Embr Thermal Device for Hot Flash Management in Prostate Cancer

This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.

The Embr thermal device is a smart device that is worn on the inside of the wrist. It is about the size of a smart watch. The Embr thermal device produces cooling or warming temperature sensations that make some people feel slightly cooler or warmer. This objective of this study is to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment. The study will take place over 4 weeks. The primary outcome is feasibility of the Embr thermal device in men with prostate cancer. Secondary outcomes include preliminary efficacy of the device, which will include the change in hot flash interference sleep measures (sleep impairment and fatigue). This is a remote study--all study assessments will be completed electronically.

Eligibility Criteria:
Inclusion Criteria:

* Have received a diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy or orchiectomy at least 1 month prior to enrollment.
* May have received prior definitive radiation therapy or surgery (\>60 days prior to study).
* Have bothersome hot flashes (occurrence ≥ 28 times per week and at least moderately bothersome).
* Presence of hot flashes for \>30 days prior to study entry.
* Have a working smartphone (iPhone 6 or greater; or Android 8.0 or greater).
* Willing to downloading and use the Embr thermal device companion app on their phone
* Willing to wear the Embr thermal device for 4 weeks, and charge and sync the device daily
* In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English

Exclusion Criteria:

* Planned treatment with chemotherapy and/or any medical intervention that will impact hot flashes, sleep, or other daily activities of daily life during the 4-week study.
* History of a known sleep disorder, other than insomnia (eg, obstructive sleep apnea, restless leg syndrome), or medical or psychiatric condition that affects sleep, or undergoing treatment for insomnia.
* History of cognitive impairment or dysfunction.
* Seizure history, history of recurrent falls, or known brain metastases.
* Uncontrolled intercurrent illness.
* Individuals with a second malignancy other than non-melanoma skin cancers.
* Individuals taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior.
* Individuals taking prescription sleep medications.
* Individuals who report consuming more than 7 alcoholic beverages/week and/or frequent alcohol consumption within 2 hours prior to bed.
Effects of Combined Cycle Training and Inspiratory Muscle Training in Patients With COPD

Chronic Obstructive Pulmonary Disease (COPD) ，the fourth leading cause of death in the world, represents an important public health challenge. It is also a major cause of chronic morbidity, mortality and disability throughout the world, leading to a heavy social and economic burden. For a long time, treatment of COPD mainly focus on drug therapy. Recently, pulmonary rehabilitation is recognized as a core component of the management of individuals with chronic respiratory disease, which has been clearly demonstrated to reduce dyspnea, increase exercise capacity, and improve quality of life.

Exercise training, widely regarded as the cornerstone of pulmonary rehabilitation , is one of the best available means of improving muscle function in COPD.The most commonly form is cycle training. Inspiratory Muscle Training (IMT) as an adjunct to exercise training has an additional benefit on inspiratory muscle strength, endurance and exercise capacity in patient with COPD.

There is insufficient evidence demonstrate greater benefits from combined inspiratory muscle training and cycle training. This study will evaluate the effects of combined inspiratory muscle training and cycle training in patients with COPD.

The patients with COPD will participate in a rehabilitation program for 8 weeks. Participants in the proposed study will be randomly programmed into one of three intervention groups:

1. Cycle training program alone (performing on calibrated stationary cycle ergometer).
2. Combined cycle training and inspiratory muscle training(performing on calibrated stationary cycle ergometer and threshold loading device).
3. Neither cycle training nor inspiratory muscle training.

Eligibility Criteria:
Inclusion Criteria:

* Patients between 40 and 75 years of age were eligible if they met the following criteria:

  * moderate to severe airflow obstruction (30≤ Forced Expiratory Volume At One Second(FEV1) \<80% predicted and Forced Expiratory Volume At One Second/Forced Vital Capacity(FEV1/FVC)\<70%)
  * Complaints of dyspnea on exertion
  * Clinically stable condition
  * No participation in a pulmonary rehabilitation program in the last year.

Exclusion Criteria:

* Patients were excluded if they had evidence of asthma and/or had experienced a major exacerbation in the 2 months before enrollment
* Required home oxygen therapy or experienced oxyhemoglobin desaturation below 85% with exercise
* And/or had other health problems that would interfere with exercise.
Massive Transfusion in Trauma Patient Registry

The early use of blood products as a part of Massive Transfusion Protocol (MTP) during trauma resuscitation has been increasingly supported by providers and backed by the literature. However, the incidence of hypocalcemia during MTP has also been recorded and continues to be studied as an exacerbating factor in coagulopathy during trauma.

Although initially it was thought that the coagulopathy was due to the trauma itself, studies suggest that it is worsened by the transfusion of blood as this is associated with increased hypocalcemia. The level of hypocalcemia is said to correlate with the amount of blood products transfused, but the number of units needed to produce a particular degree of hypocalcemia remains to be defined. A standardized value for hypocalcemia due to MTP has yet to be established. Establishing this value would be helpful in determining what level actually affects the rate of mortality. Some studies suggest intravenous calcium supplement should be considered during massive transfusion while others state this does not make a difference.

This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement.

Eligibility Criteria:
Inclusion Criteria:

* • ≥18 years old

  * Included in the Methodist dallas medical center(MDMC) trauma registry
  * Flagged for MTP activation and/or \>1unit(U) blood product recorded in the first 24 hours

Exclusion Criteria:

* • \<18 years old
mHealth-CArdiac REhabilitation for INOCA

This is a multi-site phase II, 2:1 pragmatic randomized trial of 250 participants within the NYU Langone Health (NYULH) and Emory University Medical Center system to evaluate mobile health cardiac rehabilitation (mHealth-CR) in patients who meet clinical criteria for INOCA (positive stress test for ischemia and no obstructive coronary disease on imaging). Participants will be randomized to mHealth-CR or usual care. The study intervention takes place for 3 months which is the time period for most traditional CR programs.

The overall study goals are threefold: 1) to evaluate whether an mHealth-CR intervention that includes activity tracking, weekly counseling, and exercise documentation, improves health status (i.e., symptoms, function, and quality of life) in patients with INOCA; 2) to assess efficacy in relation to sex and the Stanford Gender-Related Variables for Health Research (SGVHR) variables (i.e., caregiver strain, work strain, independence, risk-taking, emotional intelligence, social support, and discrimination); and 3) to characterize engagement and elucidate barriers to participation by sex and SGVHR variables.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 and over
* Diagnosis of Ischemia with Non-Obstructive Coronary Arteries (INOCA) based on evidence of ischemia and/or ischemic symptoms, plus non-obstructive Coronary artery disease (CAD) on computed tomography (CT) or invasive angiography

Exclusion Criteria:

* Seattle Angina Questionnaire (SAQ) = 100
* Non-ambulatory
* Pregnant
* Moderate or severe cognitive impairment
* Unable/willing to provide consent
* Incarcerated
* Unable to use mHealth
* Severe osteoarthritis or joint replacement within 3 months
* Parkinsons disease or other movement disorders
* Regular use of walker
* Life expectancy \< 12 months
* Clinical judgement concerning other safety or non-adherence issues
* Unable to read and communicate in English since the app content is currently only available in English.
Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

This study will investigate the effect of a single dose of PF-04171327 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test


Eligibility Criteria:
Inclusion Criteria:

* BMI 17.5 to 30.5 kg/m2 and total body weight \>50 kg

Exclusion Criteria:

* Fasting glucose above the limits of the reference range for healthy individuals
* "No treatment" Oral Glucose Tolerance Test (OGTT) indicative of impaired fasting glucose or impaired glucose tolerance
* Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
Ultrasound-Guided Stellate Ganglion Block With Botulinum

the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy

:Idiopathic facial nerve palsy (Bell's palsy) is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is inteneded to increase blood flow and promotes nerve regeneration. the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed by clinical and neurological assessment as one-sided idiopathic facial palsy
* Age 18 to 60 •-ASA i-II

Exclusion Criteria:

* Exclusion Criteria:

  * diabetic
  * coagulation dysfunction
  * mental or cognitive dysfunclion
  * allergy to injected medication
Acute Kidney Injury in Neonates

Our first aim is to describe how common a sudden decrease in renal function happens in infants in a neonatal intensive care unit. We also want to see how a sudden loss of renal function affects survival. Finally, we will explore non-invasive markers to identify a sudden decrease in renal function from urinary samples.

Advancements in the field of peri-natal medicine has improved the survival of critically ill neonates but yet many still do not survive, and many more are left with long-term damage to vital organ systems. Very little data is available on the impact that acute kidney injury (AKI) has on survival in term neonates, but adult and pediatric studies that show that even mild AKI independently impacts survival after correcting for severity of illness. The role that AKI impacts survival in neonates is likely to be greater than adults as this acute injury occurs in context of impaired and ongoing kidney development.

Our ability to improve outcomes in children and adults with AKI has been hampered by the inability to recognize AKI early in the disease process. Thus, the work on early non-invasive biomarkers of renal injury has brought great optimism to the field of AKI. Serum and urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), urinary interleukin 18 (IL-18) others are markedly elevated several hours after AKI as opposed to serum creatinine which takes days to rise after the inciting event. Early non-invasive biomarkers of AKI have not been tested in neonates.

Inclusion criteria - Families of infants (birthweight \>1500g) be asked to participate in the study.

Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded

Eligibility Criteria:
Inclusion Criteria:

* Families of infants (birthweight \>1500g) be asked to participate in the study.

Exclusion Criteria:

* Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent dated and signed.
* Both eyes diagnosed open-angle glaucoma or ocular hypertension

Exclusion Criteria:

* History of trauma, infection, clinically significant inflammation within the previous 3 months
* Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
* Pregnancy or breast-feeding
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.

While AIH has shown potential in enhancing neuroplasticity in people with spinal cord injury (SCI), it has yet to be studied extensively in MS. Preliminary research in the MS population demonstrates that a single session of AIH enhances motor output, increasing voluntary muscle strength by as much as 15-20% within 60 minutes. This study will explore potential mechanisms of AIH in MS using measurements of arm function, as well as examination of corticospinal and spinal motoneuron excitability.

Over the past decade, studies have found that brief episodes of modest oxygen reduction (termed AIH) can rapidly enhance neural plasticity in persons with incomplete SCI. AIH activates the serotonergic pathway, leading to increased activity of serotonin receptors and the synthesis of plasticity-related proteins. This plasticity is manifested by a rapid increase in voluntary muscle strength, emerging within 60-90 minutes, in both lower- and upper-limb muscles. The actions of AIH appear to be biologically linked to systems designed to preserve breathing systems that are impaired by damage to the central nervous system (CNS).

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago
* Relapse free for at least 6 months
* Expanded Disability Status Scale (EDSS) ≤7
* Index finger abduction strength \<5 according to Medical Research Council Scale, or 9-Hole Peg Test score \>20 seconds in at least one hand
* Stable disease modifying therapies for at least 6 months
* Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion Criteria:

* Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function
* Mini-Mental State Examination (MMSE) score \<24
* Modified Ashworth Scale score \>3 on elbow joint
* Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg)
* History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea
* Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain
* Pregnancy as confirmed by urine test
In Vitro Fertilization and Pregnancy After Use of Chemotherapy

Objective: Chemotherapy regimens containing alkylating agents result in primordial follicle death and premature ovarian failure. Depending on the age and the type/dose of chemotherapy, some women may continue to menstruate. Our aim was to ascertain the impact of chemotherapy on ovarian reserve in patients who previously received chemotherapy by response to controlled ovarian hyper stimulation (COH) and anti-mullerian hormone (AMH) levels. Design: Prospective study with retrospective controls Materials and Methods: 45 cancer patients underwent controlled ovarian stimulation for IVF before (30 patients, 30 IVF cycles) or after (15 patients, 30 IVF cycles) chemotherapy. Patients with basal serum FSH \>13mIU/mL or E2\>70pg/ml were excluded. AMH was measured on previously stored serum samples from the day of initiation of the ovarian stimulation. Results: Mean ages and baseline FSH levels of pre- and postchemotherapy IVF patients were similar (36.8±0.91 vs. 36.3±1). The mean interval from completion of chemotherapy to IVF was 8.03±1.32 years (range 1-23). Of the 30 IVF cycles in post-chemotherapy patients, 22 received alkylating agents and 8 did not.

There were no significant differences between the study and control cycles regarding day-2 estradiol (E2), length of stimulation, total gonadotropin dose, and E2 on hCG day (table 2). Cycle cancellation rate was 20% and 26.67% for pre and post-chemotherapy patients, respectively. The number of oocytes retrieved and fertilized were significantly higher in pre-chemotherapy group (p\<0.0001). Two clinical pregnancies were achieved in the postchemotherapy group, one ending in spontaneous abortion and the other in the delivery of a healthy baby (6.67% clinical pregnancy rate and 3.33% delivery rate per attempted cycle). All fertilized oocytes in the control group were cryopreserved at 2-pronuclei stage.

Baseline AMH levels were significantly lower in post chemotherapy IVF patients compared to those who underwent IVF prior to chemotherapy (0.270 ±0.077 vs. 0.84±0.27 ng/ml, p=0.03). In the pre-chemotherapy group there was a positive correlation between the AMH levels and the number of oocytes retrieved (r=0.663, p=0.004 ). This correlation was not detected in the post chemotherapy group (r=0.205).


Eligibility Criteria:
Inclusion Criteria:

* Age 18-45 years
* Histologically confirmed cancer diagnosis
* Received chemotherapy more than one year ago
* Have both ovaries
* Regular menstrual cycle
* Normal basal FSH, LH and estradiol

Exclusion Criteria:

* \>42 years
* Radiation below the diaphragm
* Ovarian failure